Patent US4454106A successfully refreshed from Google Patents.
US4454106A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Use of metal chelate conjugated monoclonal antibodies
Assignee: Johns Hopkins University
•
Filing: 1982-06-07
•
Granted: 1984-06-12
•
Expires: 2002-06-07
Abstract
Abstract Therapeutic and diagnostic methods employing metal chelate conjugated monoclonal antibodies are described. Metals employed in therapeutic conjugated antibodies include alpha particle, beta particle or Auger electron emitting isotopes. Diagnostic methods may be either in vivo or in vitro. Chelated metals employed in diagnostic techniques may include, inter alia, gamma or positron emitting metals as well as fluorogenic or paramagnetic metals.
Inventors
- 👤 Otto A. Gansow
- 👤 Mette Strand
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-27 07:09
CPC Classifications
C; C07; C07K; C07K16/00; C07K16/18; A; A61; A61K; A61K51/00; A61K51/02; A61K51/04; A61K51/08; A61K51/10; A61K51/1093; C07K16/08; C07K16/10; C07K16/112; C07K16/28; C07K16/30; C07K16/3015; A61K2121/00; Y; Y10; Y10S; Y10S436/00; Y10S436/804; Y10S436/819
Claims Analysis
Total Claims: 25
Claim 1
Independent Claim
51 words
A method of treating cellular disorders comprising introducing into body fluid a solution of radiometal chelate conjugated monoclonal antibodies specific for a target cell, said radiometal being an alpha, beta or Auger electron emitter and substantially all of said radiometal in said solution being chelated by said chelate conjugated monoclonal antibodies.
Claim 2
Independent Claim
51 words
A method of treating cellular disorders comprising introducing into body fluid a solution of radiometal chelate conjugated monoclonal antibodies specific for a target cell, said radiometal being an alpha, beta or Auger electron emitter and substantially all of said radiometal in said solution being chelated by said chelate conjugated monoclonal antibodies.
Claim 3
Dependent Claim
12 words
The method of claim 1 wherein the radiometal is an alpha emitter.
Claim 4
Dependent Claim
19 words
The method of claim 2 wherein said radiometal is selected from the group consisting of Bi-211, Bi-212 and Bi-213.
Claim 5
Dependent Claim
10 words
The method of claim 3 wherein said radiometal is Bi-212.
Claim 6
Dependent Claim
14 words
The method of claim 1 wherein said chelate is a derived from diethylenetriaminepentaacetic acid.
Claim 7
Dependent Claim
24 words
The method of claim 2 wherein said chelate conjugated monoclonal antibodies are produced from a carboxycarbonic anhydride of diethylenetriaminepentaacetic acid and a monoclonal antibody.
Claim 8
Dependent Claim
20 words
The method of claim 6 wherein said carboxycarbonic anhydride is produced form isobutylchloroformate and an amine salt of diethylenetriaminepentaacetic acid.
Claim 9
Dependent Claim
42 words
The method of claim 5 wherein said radiometal chelate conjugated monoclonal antibody solution has at least about 94% of the radiometal bound by the chelate and said conjugate retains at least about 80% of the biological activity and specificity of the antibody.
Claim 10
Dependent Claim
47 words
The method of claim 6 wherein said radiometal is Bi-212 and the metal chelate conjugated monoclonal antibody solution has at least about 98% of the radiometal bound by the chelate and said conjugate retains at least about 95% of the biological activity and specificity of the antibody.
Claim 11
Independent Claim
67 words
A method of treating cellular disorders comprising introducing into body fluid a solution of radiometal diethylenetriaminepentaacetic acid chelate conjugated monoclonal antibodies wherein said radiometal is selected from the group consisting of beta emitting radiometals and Auger emitting radiometals, at least about 94% of said radiometal being bound by said chelate, and said conjugate having at least about 80% of the biological activity and specificity of the antibody.
Claim 12
Independent Claim
67 words
A method of treating cellular disorders comprising introducing into body fluid a solution of radiometal diethylenetriaminepentaacetic acid chelate conjugated monoclonal antibodies wherein said radiometal is selected from the group consisting of beta emitting radiometals and Auger emitting radiometals, at least about 94% of said radiometal being bound by said chelate, and said conjugate having at least about 80% of the biological activity and specificity of the antibody.
Claim 13
Dependent Claim
21 words
The method of claim 10 wherein said radiometal is selected from the group consisting of Sc-46, Sc-47, Sc-48, Ga-72 and Ga-73.
Claim 14
Dependent Claim
22 words
The method of claim 10 wherein said conjugated antibody is produced from a carboxycarbonic anhydride of diethylenetriaminepentaacetic acid and a monoclonal antibody.
Claim 15
Dependent Claim
20 words
The method of claim 12 wherein said carboxycarbonic anhydride is produced from isobutylchloroformate and an amine salt of diethylenetriaminepentaacetic acid.
Claim 16
Dependent Claim
35 words
The method of claim 10 wherein at least about 98% of the radiometal is bound by the chelate and said conjugate retains at least about 95% of the biological activity and specificity of the antibody.
Claim 17
Dependent Claim
68 words
An in vivo diagnostic method comprising introducing into body fluid a solution of metal diethylenetriaminepentaacetic acid chelate conjugated monoclonal antibodies wherein said metal is selected from the group consisting of paramagnetic metals, gamma emitting metals and positron emitting metals, at least about 94% of said metal is bound by said chelate, and said conjugate has at least about 80% of the biological activity and selectivity of the antibody.
Claim 18
Dependent Claim
68 words
An in vivo diagnostic method comprising introducing into body fluid a solution of metal diethylenetriaminepentaacetic acid chelate conjugated monoclonal antibodies wherein said metal is selected from the group consisting of paramagnetic metals, gamma emitting metals and positron emitting metals, at least about 94% of said metal is bound by said chelate, and said conjugate has at least about 80% of the biological activity and selectivity of the antibody.
Claim 19
Dependent Claim
28 words
The method of claim 14 wherein said metal is selected from the group consisting of Tc-99m, In-111, Ga-67, Ga-68, Sc-43, Sc-44, Fe-52, Fe-54, Fe-56, Fe-57, Fe-58 and Co-55.
Claim 20
Dependent Claim
35 words
The method of claim 15 wherein at least about 98% of the radiometal is bound by the chelate and said conjugate retains at least about 95% of the biological activity and specificity of the antibody.
Claim 21
Dependent Claim
82 words
An in vitro diagnostic method comprising introducing into a test medium a solution of metal diethylenetriaminepentaacetic acid chelate conjugated monoclonal antibodies and quantifying the specifically bound portion of said conjugate, said metal being selected from the group consisting of fluorescent metals, paramagnetic metals, gamma emitting metals, positron emitting metals and beta emitting metals, at least about 94% of said metal being bound by said chelate, and said conjugate having at least about 80% of the biological activity and specificity of the antibody.
Claim 22
Dependent Claim
82 words
An in vitro diagnostic method comprising introducing into a test medium a solution of metal diethylenetriaminepentaacetic acid chelate conjugated monoclonal antibodies and quantifying the specifically bound portion of said conjugate, said metal being selected from the group consisting of fluorescent metals, paramagnetic metals, gamma emitting metals, positron emitting metals and beta emitting metals, at least about 94% of said metal being bound by said chelate, and said conjugate having at least about 80% of the biological activity and specificity of the antibody.
Claim 23
Dependent Claim
28 words
The method of claim 18 wherein said metal is selected from the group consisting of Tc-99m, In-111, Ga-67, Ga-68, Sc-43, Sc-44, Fe-52, Fe-54, Fe-56, Fe-57, Fe-58, and Co-55.
Claim 24
Dependent Claim
27 words
The method of claim 18 wherein said metal is selected from the group consisting of Pr, Nd, Sm, Eu, Gd, Tb, Dy, Ho, Er, Tm and Yb.
Claim 25
Dependent Claim
35 words
The method of claim 18 wherein at least about 98% of the radiometal is bound by the chelate and said conjugate retains at least about 95% of the biological activity and specificity of the antibody.
References Cited (Backward Citations)
US3961038A
Cited
US4364920A
Cited
US4196265A
Cited
US4283382A
Cited
US4323546A
Cited
US4311688A
Cited
US4331647A
Cited
US4348376A
Cited
US4361544A
Cited
US4339426A
Cited
EP0038546A2
Cited
EP0066786A2
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1987-06-12 | 1987-12-12 | 1988-06-12 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1991-06-12 | 1991-12-12 | 1992-06-12 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1995-06-12 | 1995-12-12 | 1996-06-12 | $7700.00 | Window Closed / Lapsed |